HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced it will host a conference call on August 13, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
The company’s platform technology is designed for portable devices that collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, all without cables. This innovation allows physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology.
The upcoming call is significant as it will provide insights into the company's financial health and strategic initiatives following these regulatory milestones. Investors and stakeholders will be keen to understand how HeartBeam plans to commercialize its platform and drive adoption among healthcare providers and patients. The ability to perform remote, cable-free 12-lead ECGs could transform cardiac care by enabling earlier detection and continuous monitoring of conditions like arrhythmias, potentially reducing hospital visits and improving patient outcomes.
For more details, the full press release is available at https://ibn.fm/sqGLs. Additional information about HeartBeam and its technology can be found in the company’s newsroom at https://ibn.fm/BEAT, and the cleared indications for use are detailed at https://www.heartbeam.com/indications.
